Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Loses Moot Appeal On Canadian Zytiga Bar

Second Action Favored Apotex In January 2021

Executive Summary

Apotex fell again in its bid to prove that a key patent in Canada shielding Janssen’s Zytiga (abiraterone acetate) treatment for prostate cancer was obvious. However, the company had already succeeded in obtaining a marketing authorization in a separate action.

You may also be interested in...



Top Players In Clear After US Court Confirms Abiraterone Patent Is Invalid

The sole US patent listed against Janssen’s Zytiga abiraterone prostate-cancer treatment is invalid, the US Court of Appeals has confirmed after generics entered the market in November last year.

Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences

Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.

Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia

Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel